温馨提醒:文章旨在传递疾病知识,不作为诊疗方案推荐及医疗依据。
封面图片来源:摄图网
责任编辑:觅健美美
[1] Yuan P, Hu X, Sun T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer. 2019;112:57-65.
[2] Bardia A, Hurvitz SA, Tolaney SM, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384(16):1529-1541.
[3] Binghe Xu, et al. Sacituzumab tirumotecan (SKB264/MK-2870) in patients (pts) with previously treated locally recurrent or metastatic triple-negative breast cancer (TNBC): Results from the phase III OptiTROP-Breast01 study.2024 ASCO. Abstract 104.
[4] 2024 年 06 月 25 日药品批准证明文件送达信息 . Retrieved June 25, 2024. From https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20240625150543149.html.